Akebia Therapeutics Inc. buy BTIG Research
Start price
29.10.25
/
50%
€1.93
Target price
29.10.26
€4.29
Performance (%)
-59.24%
Price
20.08.26
€0.75
Summary
This prediction is currently active. The BUY prediction by BTIG_Research for Akebia Therapeutics Inc. is performing very badly with a performance of -59.24%. This prediction currently runs until 29.10.26. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | -0.266% | -0.266% |
| iShares Core DAX® | -1.586% | 5.028% |
| iShares Nasdaq 100 | -4.148% | -0.125% |
| iShares Nikkei 225® | -6.302% | 0.528% |
| iShares S&P 500 | -3.225% | 0.470% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.18
07.04.26
07.04.26
€3.47
07.04.27
07.04.27
-36.21%
20.08.26
20.08.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.08
25.02.26
25.02.26
€3.39
25.02.27
25.02.27
-26.97%
20.08.26
20.08.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.27
02.12.25
02.12.25
€4.31
02.12.26
02.12.26
-38.32%
20.08.26
20.08.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
122.78%
30.11.24
30.11.24